• 1
    Galsky MD, Mosheer E. Krege S, et al. Nomogram for predicting survival in patients with resectable and/or metastatic urothelial cancer treated with cisplatin-based chemotherapy. Cancer. 2013;119:30123019.
  • 2
    Galsky MD, Krege S, Lin C-C, et al. Relationship between 6- and 9-month progression free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer. 2013;119:30203026.
  • 3
    Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:31733181.
  • 4
    De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191199.
  • 5
    Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:11071113.
  • 6
    Apolo AB, Ostrovnaya I, Halabi S, et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013;105:499503.
  • 7
    Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:13641370.
  • 8
    Harrell FE Jr. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer Verlag; 2001.
  • 9
    Anderson J, Cain K, Gelber R. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710719.